Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.

被引：0

作者：

Pemmaraju, Naveen

Yu, Jingbo

Parasuraman, Shreekant

Paranagama, Dilan

Kish, Jonathan

Visaria, Jay

Singhal, Mukul

Verstovsek, Srdan

Gerds, Aaron Thomas

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Incyte Corp, Wilmington, DE USA

[3] Cardinal Hlth, Dublin, OH USA

[4] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[5] Case Comprehens Canc Ctr, Cleveland, OH USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e19535

引用

页数：2